Astellas Pharma Inc. (ALPMY.PK, ALPMF.PK) Thursday announced a collaboration with Ambrx Inc., a clinical stage biopharmaceutical company, for the discovery and development of novel antibody drug conjugates or ADCs.
ADCs allow for the targeted delivery of drugs to the focus tissue. Ambrx creates optimized ADCs using its site-specific conjugation technology along with proprietary linkers and payloads.
In the preclinical setting, Ambrx ADCs have demonstrated high potency and a wider therapeutic index than ADCs created using conventional non-specific conjugation.
Ambrx will receive an upfront payment of $15 million from Astellas, as well as up to $285 million in potential research, development, regulatory and sales-based milestones for an undisclosed number of targets for ADCs in oncology.
A portion of these milestones, as well as royalties on any net sales, will be contingent on eventual successful commercialization of products developed as a result of this partnership, Astellas said.
On its part, Astellas will receive worldwide rights to develop and commercialize ADCs for oncology. Additional terms of the collaboration were not disclosed.
For comments and feedback: editorial@rttnews.com